SOD1 and Parkinson disease: We also consider therapies capable of restoring the physiological maturation of SOD1, through improved metalation [1, 36] or stabilization of the protein [9], to possess potential in mitigating nigrostriatal degeneration in Parkinson disease by simultaneously ameliorating SOD1 pathology and combating oxidative stress.